Privia Health Group (PRVA) to Release Earnings on Thursday

Key Points

• Privia Health Group (PRVA) is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of $0.05 per share and revenue of $466.97 million.
• Recent analyst ratings show strong confidence in the stock, with a consensus rating of "Buy" and a target price of $28.38.
• CEO Parth Mehrotra and CFO David Mountcastle both sold shares recently, which represents a decrease in their ownership but highlights continued executive activity in the market.

Privia Health Group (NASDAQ:PRVA - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $466.97 million for the quarter.

Privia Health Group Stock Down 3.4%

Shares of NASDAQ:PRVA traded down $0.66 on Friday, reaching $18.86. 766,405 shares of the company's stock were exchanged, compared to its average volume of 798,883. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of 157.18, a PEG ratio of 3.12 and a beta of 0.80. Privia Health Group has a fifty-two week low of $16.47 and a fifty-two week high of $26.09. The business's 50-day moving average is $21.62 and its two-hundred day moving average is $22.90.

Insider Transactions at Privia Health Group

In other news, CEO Parth Mehrotra sold 13,773 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $24.99, for a total transaction of $344,187.27. Following the completion of the transaction, the chief executive officer owned 423,143 shares in the company, valued at approximately $10,574,343.57. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO David Mountcastle sold 3,322 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $24.99, for a total transaction of $83,016.78. Following the transaction, the chief financial officer owned 172,909 shares of the company's stock, valued at approximately $4,320,995.91. This trade represents a 1.89% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.70% of the company's stock.

Hedge Funds Weigh In On Privia Health Group

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new position in shares of Privia Health Group during the 1st quarter valued at about $154,000. AQR Capital Management LLC boosted its position in shares of Privia Health Group by 24.7% during the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company's stock valued at $916,000 after purchasing an additional 8,068 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Privia Health Group by 55.1% during the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company's stock valued at $1,270,000 after purchasing an additional 20,082 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Privia Health Group by 3.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company's stock valued at $2,666,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Privia Health Group by 63.5% during the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company's stock valued at $5,514,000 after purchasing an additional 95,371 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Analysts Set New Price Targets

PRVA has been the topic of a number of research reports. JMP Securities reissued a "market outperform" rating and set a $29.00 target price on shares of Privia Health Group in a report on Monday, April 28th. Evercore ISI dropped their price objective on shares of Privia Health Group from $30.00 to $28.00 and set an "outperform" rating on the stock in a report on Wednesday, July 9th. Barclays increased their price objective on shares of Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a report on Tuesday, May 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Privia Health Group in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $28.38.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.